OTCMKTS:ARTH - Arch Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.3950 +0.02 (+5.33 %) (As of 11/21/2018 09:52 AM ET)Previous Close$0.38Today's Range$0.3950 - $0.395052-Week Range$0.25 - $0.80Volume1,605 shsAverage Volume171,529 shsMarket CapitalizationN/AP/E Ratio-7.90Dividend YieldN/ABeta0.83 ProfileDiscussionAnalyst RatingsChartEarningsHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Arch Therapeutics, Inc., operates as a biotechnology company in the United States. The company develops products based on its technology to stop bleeding and control leaking, as well as provides other advantages during surgery, trauma, and interventional care. Its primary product candidate is AC5 Devices, a synthetic biocompatible peptides that comprises naturally occurring amino acids to achieve hemostasis in minimally invasive and open surgical procedures. The company was founded in 2006 and is based in Framingham, Massachusetts. Receive ARTH News and Ratings via Email Sign-up to receive the latest news and ratings for ARTH and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:ARTH Previous SymbolNASDAQ:ARTH CUSIPN/A Webwww.archtherapeutics.com Phone617-431-2313 Debt Debt-to-Equity RatioN/A Current Ratio18.77 Quick Ratio18.77 Price-To-Earnings Trailing P/E Ratio-7.90 Forward P/E Ratio-13.17 P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book Value$0.01 per share Price / Book39.50 Profitability EPS (Most Recent Fiscal Year)($0.05) Net Income$-7,780,000.00 Net MarginsN/A Return on Equity-253.72% Return on Assets-115.60% Miscellaneous Employees10 Outstanding Shares159,820,000Market Cap$0.00 OptionableNot Optionable Arch Therapeutics (OTCMKTS:ARTH) Frequently Asked Questions What is Arch Therapeutics' stock symbol? Arch Therapeutics trades on the OTCMKTS under the ticker symbol "ARTH." How were Arch Therapeutics' earnings last quarter? Arch Therapeutics Inc (OTCMKTS:ARTH) posted its quarterly earnings results on Tuesday, May, 2nd. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.01). View Arch Therapeutics' Earnings History. When is Arch Therapeutics' next earnings date? Arch Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, November 21st 2018. View Earnings Estimates for Arch Therapeutics. What price target have analysts set for ARTH? 4 analysts have issued twelve-month price objectives for Arch Therapeutics' shares. Their predictions range from $3.00 to $3.00. On average, they expect Arch Therapeutics' share price to reach $3.00 in the next year. This suggests a possible upside of 659.5% from the stock's current price. View Analyst Price Targets for Arch Therapeutics. What is the consensus analysts' recommendation for Arch Therapeutics? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arch Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Arch Therapeutics. Has Arch Therapeutics been receiving favorable news coverage? Headlines about ARTH stock have trended positive recently, according to InfoTrie. The research group identifies negative and positive media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Arch Therapeutics earned a daily sentiment score of 2.1 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 3.0 out of 10, meaning that recent media coverage is unlikely to have an effect on the stock's share price in the next few days. Who are some of Arch Therapeutics' key competitors? Some companies that are related to Arch Therapeutics include AdvanSource Biomaterials Corpration (ASNB), AIT Therapeutics (AITB), Biostage (BSTG), Calmare Therapeutics (CTTC), Delcath Systems (DCTHD), Delcath Systems (DCTH), FRESENIUS SE &/S (FSNUY), Hypertension Diagnostics (HDII), Invo Bioscience (IVOB), Invuity (IVTY), Nephros (NEPH), Oncologix Tech (OCLG), OxySure Therapeutics (OXYS), RenovaCare (RCAR) and Repro-Med Systems (REPR). Who are Arch Therapeutics' key executives? Arch Therapeutics' management team includes the folowing people: Dr. Terrence W. Norchi, Co-Founder, Pres, CEO, Sec. & Director (Age 53)Mr. Richard E. Davis, Chief Financial Officer and Treasurer (Age 60)Dr. Avtar S. Dhillon, Bus. Advisor (Age 57)Mr. Rutledge Ellis-Behnke, Co-Founder & Scientific AdvisorDr. Steven A. Kates Ph.D., VP of Technology How do I buy shares of Arch Therapeutics? Shares of ARTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Arch Therapeutics' stock price today? One share of ARTH stock can currently be purchased for approximately $0.3950. What is Arch Therapeutics' official website? The official website for Arch Therapeutics is http://www.archtherapeutics.com. How can I contact Arch Therapeutics? Arch Therapeutics' mailing address is 235 WALNUT STREET SUITE 6, FRAMINGHAM MA, 01702. The biotechnology company can be reached via phone at 617-431-2313 or via email at [email protected] MarketBeat Community Rating for Arch Therapeutics (OTCMKTS ARTH)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 134 (Vote Outperform)Underperform Votes: 129 (Vote Underperform)Total Votes: 263MarketBeat's community ratings are surveys of what our community members think about Arch Therapeutics and other stocks. Vote "Outperform" if you believe ARTH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARTH will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 11/21/2018 by MarketBeat.com StaffFeatured Article: What is the Dow Jones Industrial Average (DJIA)?